Drug intelligence / Profile preview

PegHeberon

Development stage: Unknown
Lead developer: Center for Genetic Engineering and Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

PegHeberon (peginterferon alfa-2b) is a pegylated formulation of recombinant interferon alpha-2b developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba. It consists of interferon alpha-2b covalently linked to a 12 kDa monomethoxy-polyethylene glycol (PEG) moiety, which significantly extends the drug's half-life compared to non-pegylated interferon, allowing for once-weekly subcutaneous administration. The drug functions as an agonist of the type I interferon receptor (IFNAR), initiating a JAK-STAT signaling pathway that induces the expression of antiviral proteins and modulates the host immune response. In the context of clinical research in Bangladesh, PegHeberon was utilized as the standard-of-care control arm in a Phase III trial comparing its efficacy against the therapeutic vaccine NASVAC for the treatment of chronic hepatitis B (CHB).

Brand names: PegHeberon
Other names: peginterferon alfa-2bpegylated interferon alpha-2bPEG-IFN alpha-2b

Targets

IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)

Beyond the preview

Go deeper on PegHeberon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PegHeberon.

Explore the full profile